Abologix news
Abologix develops a new therapeutic option to treat lymphoma patients who have become resistant to conventional treatments. The Geneva-based biotech startup is a spin-out from the laboratories at the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG). Abologix will use the CHF 150,000 to advance the preclinical development of its product, refine its commercial and competitive positioning, and strengthen its business development and fundraising efforts.
B-cell lymph
Abologix has been granted a 2 year Innosuisse Innovation project in collaboration with the University Hospital of Geneva (HUG). The HUG will be the research partner and Abologix the implementation partner.The collaboration plans to study the mechanism of action involved in arresting tumour growth through the selective blocking of Junction Adhesion Molecule JAM-C by monoclonal antibodies supplied by Abologix. These studies will lead to a deeper understanding of the molecular mechanisms o
Abologix has received recognition in “Bilan” as one of the most promising swiss start-ups in the french speaking cantons of Switzerland. The company has been invited to address a group of potential investors in a future meeting to be held in Lausanne, Switzerland.
Abologix has obtained impressive data with its anti-JAM-C recombinant monoclonal antibody rH225 in an animal Mantle Cell Lymphoma (MCL) NOD/SCID mouse model.
In this study the efficacy of rH225 was tested by assessing:
- the delayed mortality upon Jeko-1 MCL cell injection and
- the reduction of Jeko-1 cells burden in the blood, spleen, lymph nodes, bone marrow and liver
rH225 delayed significantly the body weight l
Abologix has entered into an exclusive, worldwide in-license agreement with Research Development Foundation for two monoclonal antibodies for oncological indications that were developed at the University of Geneva with funding from Institut Clayton de la Recherche.
During the past 10+ years Institut Clayton de la Recherche has funded research at the laboratories of Prof. Beat Imhof and Thomas Matthes at the University of Geneva, mostly in the understanding of the bi